1 week Ago By ABMN Staff
Norges Bank purchased a new stake in shares of Pacira BioSciences, Inc. ( NASDAQ:PCRX – Free Report ) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 127,655 shares of the company’s stock, valued at approximately $2,405,000.
Other hedge funds have also added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Pacira BioSciences by 5.8% in the third quarter.
State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after purchasing an additional 110,162 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pacira BioSciences by 16.
3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock valued at $9,462,000 after acquiring an additional 70,307 shares in the last quarter.
Nisa Investment Advisors LLC lifted its stake in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter.
Empowered Funds LLC grew its stake in shares of Pacira BioSciences by 5.1% in the 4th quarter. Empowered Funds LLC now owns 229,485 shares of the company’s stock worth $4,323,000 after acquiring an additional 11,149 shares in the last quarter.
Finally, Gagnon Securities LLC grew its stake in shares of Pacira BioSciences by 4.8% in the 4th quarter. Gagnon Securities LLC now owns 321,743 shares of the company’s stock worth $6,062,000 after acquiring an additional 14,800 shares in the last quarter.
Institutional investors and hedge funds own 99.73% of the company’s stock. Pacira BioSciences Stock Up 3.
7 % Shares of NASDAQ PCRX opened at $24.56 on Friday. The company has a debt-to-equity ratio of 0.
51, a current ratio of 2.25 and a quick ratio of 1.89.
The stock has a market capitalization of $1.14 billion, a PE ratio of -12.10 and a beta of 0.
71. Pacira BioSciences, Inc. has a one year low of $11.
16 and a one year high of $31.67. The business’s fifty day moving average price is $24.
74 and its 200-day moving average price is $20.81. Analysts Set New Price Targets Read Our Latest Stock Analysis on PCRX Pacira BioSciences Profile ( Free Report ) Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway.
Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. See Also Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. ( NASDAQ:PCRX – Free Report ). Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
